Erschienen in:
26.07.2022 | ASO Author Reflections
ASO Author Reflections: Neoadjuvant Treatment for Melanoma—Where Are We Now?
verfasst von:
Cimarron E. Sharon, MD, Giorgos C. Karakousis, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 13/2022
Einloggen, um Zugang zu erhalten
Excerpt
Management of patients with resectable stage III–IV cutaneous melanoma historically consisted of surgical resection upfront with consideration of adjuvant therapy. However, with the advent of systemic therapies (i.e., targeted therapy and immune checkpoint blockade) with significant antitumor activity, there has been an increasing interest in neoadjuvant approaches to patients with oligometastatic disease. Neoadjuvant therapy is advantageous as it can both downstage the tumor and theoretically “prime” the immune system to the circulating tumor antigens prior to resection. …